H.C. Wainwright maintained a positive stance on Esperion Therapeutics (NASDAQ:ESPR) shares, reaffirming a Buy rating and a price target of $16.00. According to InvestingPro data, analyst targets for ...

JMP Securities lowered the firm’s price target on Esperion (ESPR) to $4 from $7 and keeps an Outperform rating on the shares. JMP updated its ...

JMP Securities adjusted its price target for Esperion Therapeutics (NASDAQ:ESPR) shares, lowering it to $4.00 from the previous $7.00. Currently trading at $1.86, the stock sits well below analyst ...

Shares in Esperion Therapeutics lost more than half of their value after it disclosed a dispute with Daiichi Sankyo on a $300 million milestone payment relating to cholesterol drug Nexletol.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report), Enanta Pharmaceuticals ...

Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) ...

Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Esperion (ESPR) with an Overweight rating and $8 price target. The company markets the oral ATP-citrate lyase inhibitors, Nexletol ...

At the beginning of May, Pfizer spun back out Esperion Therapeutics, which it had originally purchased for $1.3 billion in March 2004. Since the acquisition, most of Esperion's promising pipeline ...

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...